UnitedHealth Group's stock price saw a slight increase to $577.29 from its last close of $577.07, even as the company faces a lawsuit from the Federal Trade Commission (FTC) over alleged insulin price inflation. The FTC has accused UnitedHealth's Optum, along with CVS Health’s Caremark and Cigna’s Express Scripts, of manipulating insulin prices through a "perverse drug rebate system," which allegedly led to a 1,200% price increase for Humalog from 1999 to 2017. Despite the legal challenges, UnitedHealth's stock opened at $571.70, reaching an intraday high of $578.31 and a low of $569.65, remaining well below its 52-week high of $607.94. The lawsuit aims to lower insurance premiums and wholesale drug prices, potentially impacting the broader pharmaceutical market. While CVS shares fell 1.8%, UnitedHealth and Cigna shares experienced only slight dips, indicating investor resilience amid the unfolding legal proceedings. The FTC's action underscores growing scrutiny of pharmacy benefit managers, which control a significant portion of the U.S. prescription market.